All posts by imreal

AZ Labs is developing a novel delivery system to deliver zinc directly into the lungs helps alleviate symptoms of the common cold/viral infections


AZ Labs is developing this innovative, patent pending, formulation as a homeopathic solution that helps alleviate symptoms of viral respiratory ailments. The product, Azvirex™, is intended to be a preventative or therapeutic aid that inhibits viral replication. Azvirex™, is in final development stages and agreements are in place with contract manufacturers to manufacture, package and market this unique homeopathic remedy.

The homeopathic product, Azvirex™ utilizes simple vaporization technology to deliver atomized zinc directly into the targeted organ, the lungs. This directeded delivery of zinc to the lower respiratory tract is intended to prevent and/or inhibit viral replication pathways of RNA viruses and other viral types (2,3,4) as well as some bacteria.

The Azvirex ™ formulation is based on multiple in-vitro and in-vivo studies that have demonstrated the efficacy of zinc ions in preventing and or inhibiting viral replication. Peer reviewed studies have shown zinc is involved in numerous aspects of cellular metabolism and is required for the catalytic activity of approximately 100 enzymes (5,6) and plays a key role in immune function (7,8).

Treatment with Azvirex ™ should provide similar or superior effectiveness for preventing or limiting the duration of the common cold (9) as compared to zinc lozenges and nasal sprays as it directly delivers zinc ions to both the upper and lower respiratory tract. These are the critical areas commonly affected by viral infections

For more information regarding AZ Labs Azvirex ™ formula, please visit http://www.azlabsnc.com. If you have any questions regarding information in the press release, please contact Max Azevedo at (828) 292-1905

1. Efficacy of Zinc Against Common Cold Viruses: An Overview Darrell Hulisz

2.Te Velthuis A., Van Den Worm S, Sims A, Barie R, Snijder E, Van Hermert M. Zn2+ inhibits coronavirus and arterivrus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. PLoS Pathog. 2010 Nov: 6(11) [ 1 0.13 71 ljouma l.pp at.100 1176 ]

3.Suara RO, Crowe JE Jr. Effects of zinc salts ofrespiratory syncytical virus replication. Antimicrob Agents Chemother., 2004 Mar, 48(3): 783-90.

4.Ishida, T. Antiviral activities of Zn2+ ions for viral prevention, replication, capsid protein and intracellular proliferation of viruses. WSN 97, 2018: 28-50.

5.Sandstead HH. Understanding zinc: recent observations and interpretations. J Lab Clin Med 1994;124:322-7. [PubMed abstract]

6.Institute of Medicine, Food and Nutrition Board. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Washington, DC: National Academy Press, 2001.

7.Solomons NW. Mild human zinc deficiency produces an imbalance between cell-mediated and humoral immunity. Nutr Rev 1998;56:27-8. [PubMed abstract]

8.Prasad AS. Zinc: an overview. Nutrition 1995;11:93-9. [PubMed abstract]

9.Prasad AS, Beck FW, Bao B, Snell D, Fitzgerald JT. Duration and severity of symptoms and levels of plasma interleukin-1 receptor antagonist, soluble tumor necrosis factor receptor, and adhesion molecules in patients with common cold treated with zinc acetate. J Infect Dis 2008 ;197:795-802. [PubMed abstract]

Share article on social media or email:

Tremor Successfully Clears World’s First Programmatic ILW Trade


On April 2nd, Tremor opened weekly online Industry Loss Warranty (ILW) auctions to provide an active marketplace to transact coverage. While most re/insurance markets continue to remain challenged or closed entirely and while many intermediaries are calling for automatic contract extensions, Tremor is seeing rapid growth in the use of its fully online, programmatic marketplace to price and allocate re/insurance programs.

Each week, Tremor posts a range of common ILWs for auction. Interested parties submit blind, sealed bids to buy and/or sell the posted ILWs; parties are not known to each other until trade is successfully completed. Upon the close of bidding, Tremor computes a market clearing price for each ILW and reports consequent trades.

Tremor completed its second weekly auction on April 9th. Capacity offered nearly tripled with twice the number of bidders from the opening week of trade. Bidders offered $87 million of capacity equally across three structures. The US Wind and Earthquake ILW contract traded at a rate on line of 12.5% before brokerage. As previously announced, Tremor will report clearing prices and spread to the market in an effort to increase ILW transparency and to further encourage trade. The details of the most recent week’s auction results can be found below:

Tremor ILW Trading Results: 9 April 2020

ILW Cleared Trades (ROL):

$50bn US Wind and Earthquake: 12.25%

Spreads (ROL):

$30bn FL Wind: 12.00% (Buy) 12.50% (Sell)

$15bn Japan Wind: 2.75% (Buy) 6.75% (Sell)


  • Clearing Price and Spread do not include commissions and fees

Anonymized aggregate supply, showing total supply available at various prices, has been made available to markets that bid on the Tremor platform.

“The team at Tremor is thrilled to have yet again broken new ground to clear the world’s first programmatic ILW trade. In just our second week of trading, capacity tripled and the number of bidders more than doubled. The feedback we have received has been fantastic – the market has endorsed that this is how ILWs should trade and Tremor’s powerful matching engine technology is the perfect solution to enable ongoing ILW trade with capacity on demand and an efficient market clearing mechanism,” said Sean Bourgeois, Founder & CEO of Tremor.

Tremor continues to work on a number of traditional placements in addition to its continuous ILW market. As the midyear renewals approach, the company has seen unprecedented demand for its technology to enable trade.

“We are thrilled to see the fruits of our labor accelerate so rapidly. Clearing trades while contemplating rich and diverse sets of preferences is a complex computational problem to solve. Our world class team has spent the last two years building our marketplace from the ground up with these capabilities in mind. Tremor combines modern marketplace liquidity technology while maintaining traditional relationships. This is precisely what the market needs now, and will require in the future,” continued Bourgeois.

Tremor’s weekly ILW marketplace welcomes buyers of protection, their brokers and sellers of protection to trade. The Tremor marketplace includes over 80 global reinsurers from all major markets, a number of reinsurance brokers, ILS funds and direct access to capacity at Lloyd’s. The company’s unique offering supercharges trading while involving the entire trading community.

Tremor will continue to auction common ILW structures every Thursday with bids accepted from 9am ET until 9am ET on Friday. Tremor will report results at the end of the trading day each Friday to participants and report results publicly thereafter.

About Tremor: Tremor is a venture-backed insurance technology firm where world class computer scientists, economists, market designers and industry practitioners are working together to build a modern risk transfer marketplace. Tremor’s “smart market” platform incorporates intelligent market design, state-of-the-art auction technology and sophisticated optimization techniques to vastly improve how risk is transferred around the world.

Share article on social media or email:

Kerastem Publishes Successful US Phase 2 Hair Growth Clinical Trial Results


Positive results from Kerastem’s Phase 2 clinical trial in early-stage hair loss patients, known as the STYLE study, were published in the Aesthetic Surgery Journal (https://doi.org/10.1093/asj/sjaa037). The STYLE study evaluated the effect of Puregraft purified fat + Adipose Derived Regenerative Cells (ADRCs) in different doses in a single procedure. Patients were followed up to 1-year. In men with early stage hair loss, the investigators reported a statistically significant increase in mean terminal (mature) hair count in men who received Puregraft fat + a low dose of ADRCs when compared to the control group at 6-months. Based on the positive results, Kerastem plans to move the technology forward in a phase 3 clinical trial.

Kerastem therapy is a one-time treatment that delivers adipose (fat) derived regenerative cells combined with purified fat to the affected area of the scalp. The Phase 2 trial was a U.S. 70 patient, multi-center, randomized, single-blinded, and controlled clinical trial to assess the safety, tolerability, dosing and hair counts in patients with early hair loss.

“Our Phase 2 study showed the Kerastem treatment stimulates hair growth in early stage male hair loss,” said Bran Conlan, CEO of Kerastem. “If our Phase 3 trial is successful, more than 40 million people in the United States with early stage hair loss would have a new option.

STUDY RESULTS


  • Low dose Adipose Derived Regenerative Cells (ADRCs) + Puregraft fat treatment group achieved a statistically significant increase in mean terminal hair count, at 6 months, when compared to control, in males with early (Grade III) stage hair loss relative to control, an average increase of 29 terminal (mature) hairs per cm2 of scalp was observed, corresponding to a 17% increase (p < 0.05).
  • All treatment arms of STYLE were safe with no serious adverse events reported.

“STYLE indicates that the dosing of this autologous cell product and tissue preparation can play a role in achieving a successful outcome,” explained Principal Investigator Ken Washenik, M.D., Ph.D., Clinical Assistant Professor in the Ronald O. Perelman Department of Dermatology, NYU School of Medicine & Medical Director, Bosley Medical Group. “To identify the optimal procedure, we designed STYLE to evaluate controls with and without the addition of autologous fat as well as both high and lower doses of ADRCs doses and determined that 500,000 cells per square centimeter resulted in a superior outcome. In short, dose matters.”

Kerastem’s planned Phase 3 trial will support a Pre-Market Approval (PMA) filing in the United States for males with early hair loss. The company will also explore other product pipeline expansion opportunities including the Kerastem treatment for females with patterned hair loss.

ANDROGENETIC ALOPECIA MARKET SIZE

Hair loss affects more than 40 million men and over 21 million women and in the United States alone. The global hair loss treatment market generates more than $7 Billion annually and currently has limited options for men and women with early stage hair loss.

ABOUT KERASTEM

Kerastem is the leader in the development and commercialization of cell-based approaches to hair growth. The company is a wholly owned subsidiary of Bimini Health Tech. The Bimini portfolio also includes Puregraft, the world’s leading fat transfer solution.

Share article on social media or email:

INOX develops antimicrobial coating for commercial and residential door hardware, preventing growth of harmful bacteria by up to 99.9%


INOX MicroArmor Antimicrobial Coating is a powder coating infused with antimicrobial technology that works to inhibit the growth and reproduction of harmful bacteria, mold and mildew by up to 99.9%.

In light of the current ongoing health crisis, it was incredibly important to us to focus our research and development on products that can help lessen the spread of harmful bacteria and to make them available to hospitals and healthcare facilities as soon as possible.

INOX® is now offering an antimicrobial coating for its line of stainless steel products, including commercial and residential door levers and pulls, deadbolts, panic devices and push/pull plates. INOX MicroArmor™ Antimicrobial Coating is a powder coating infused with antimicrobial technology that is applied during the hardware’s manufacturing process and works to inhibit the growth and reproduction of harmful bacteria, mold and mildew by up to 99.9%.

“In light of the current ongoing health crisis, it was incredibly important to us to focus our research and development on products that can help lessen the spread of harmful bacteria and to make them available to hospitals and healthcare facilities as soon as possible,” said Qianyan Cheng, INOX Co-Founder and Vice President of Product Development.

TWEET THIS: Door #hardware company @INOX_Hardware will offer an antimicrobial coating for its stainless steel products, including residential and commercial door levers and pulls. The coating inhibits the growth of harmful bacteria by up to 99.9% bit.ly/INOX_MicroArmor #COVID19

INOX MicroArmor Antimicrobial Coating contains silver ions that attach themselves to a microbe’s cellular enzyme to inhibit the growth of the microbe, reducing the spread of bacteria, fungi and mold. During the manufacturing process, the powder coating is applied to an INOX product and the silver ions within the coating integrate with the product itself. This enables the hardware to have 24/7, around-the-clock protection that does not wash off or wear away and remains effective in reducing the growth and spread of bacteria.

The antimicrobial technology infused in MicroArmor is approved by the Environmental Protection Agency (EPA). INOX MicroArmor is also certified by the Japanese Industrial Standard (JIS) Z 2801 method.

INOX MicroArmor Antimicrobial Coating is immediately available as an additional option for builders and specifiers. For more information, please visit inoxproducts.com.

About INOX

INOX is an innovative engineering company that designs and manufactures premium decorative hardware and door locks, including its industry-exclusive Privacy Barn Door Lock. For more than 25 years, INOX has been an expert in door hardware design with a proven track record of supplying product for some of the largest projects in North America, South America and around the world. INOX products are distributed worldwide via a network of more than 500 high-end retail designer hardware showrooms and distributors. To learn more about INOX, visit http://www.inoxproducts.com.

Share article on social media or email:

MaintenX International Wants Facility Managers to Plan Ahead


A MaintenX emergency response team members stands in front of an emergency supply truck, helping a customer.

MaintenX’s emergency response team can help facility managers plan, prepare and recover from any storm.

Scheduling preventative maintenance services early ensures roof inspections, debris clearing, plumbing repairs and other recommended hurricane preparations can be completed with time to spare before June arrives.

So far, 2020 has not been a year for the faint of heart. Facility managers around the world have had to manage store closures, modified hours, and new social distancing protocols due to the novel coronavirus. While it’s important to focus on employee and customer well-being during these trying times, it’s also important to not lose sight of potential issues to come. For facility managers on the East and Gulf Coasts of the United States, that means preparing for the 2020 Atlantic Hurricane Season, which is only six weeks away.

Already, Colorado State University is predicting a more-active-than-usual year. The season, which runs from June 1 through November 30, is predicted to result in 16 named storms and eight hurricanes, four of which will qualify as “major hurricanes.”

“Don’t wait to start planning for hurricane season,” said Bill Schaphorst, VP of Business Development at MaintenX. “It doesn’t take a major storm to create major damage. Preparations done now go a long way to help ensure facilities are ready to weather any storm.”

MaintenX is considered an essential business during the COVID-19 outbreak, so their Disaster Recovery and Rapid Response Team is ready to help customers prepare their facilities for the extreme weather that may come. Scheduling preventative maintenance services early ensures roof inspections, debris clearing, plumbing repairs and other recommended hurricane preparations can be completed with time to spare before June arrives.

Working with maintenance professionals to craft a formal hurricane plan can help ensure facility managers have supplies and communication channels ready. Especially while our supply systems and essential store workers are being taxed due to the pandemic, allowing additional time for preparation is wise. Even in normal times, a last-minute rush for hurricane materials and facility vendors can cause facility managers to find themselves empty handed.

To learn more about MaintenX, or to schedule a planning call with one of their knowledgeable technicians, visit http://www.maintenx.com.

ABOUT MAINTENX INTERNATIONAL:

MaintenX International is a fully licensed, facilities repair company. As one of the largest national self-performing facility maintenance and repair companies in the U.S., MaintenX has created a wide network of knowledgeable and professional technicians throughout the country. With their team of well-trained technicians, MaintenX self-performs and manages facility maintenance for their clients. In the event there is not a MaintenX technician in an area, the company has established a network of preferred vendor partners throughout the country for continued superior service for their clients. For more than 40 years, MaintenX has been expertly serving multi-location retail stores, restaurant chains and Fortune 500 companies nationwide.

Share article on social media or email:

Ziegler Closes $61 Million Series 2020 Bonds For Van Wert County Hospital Association


Ziegler, a specialty investment bank, is pleased to announce the successful closing a $61,290,000 Series 2020 bond issue for Van Wert County Hospital Association (d/b/a Van Wert Health) located in Van Wert, Ohio and issued through the county of Van Wert.

The proceeds of the bonds will be used to complete the construction of an 80,000 square foot expansion of its main campus adding much-needed modern medical, surgical and labor and delivery space. The proceeds of the bonds were also used to refinance certain existing debt of Van Wert Health.

Ziegler was retained by Van Wert Health in the summer of 2019 to assess a unique credit situation for the 27-bed rural healthcare provider. Ziegler’s initial assessment led it down a focused path of finding a capital partner that could provide affordable financing and certainty of execution. After performing a comprehensive solicitation, Preston Hollow Capital LLC surfaced as the investor best positioned to deliver on the goals of Van Wert Health and was able to deliver capital on time in challenging market conditions. The limited public offering provides 30-year committed capital for Van Wert Health.

Ziegler is a premier investment bank to community and regional healthcare providers. For over 80 years, we have been assisting these organizations with creative, tailored financial solutions for their capital needs. Specializing in healthcare, Ziegler offers an array of services including investment banking, financial risk management, merger and acquisition services, as well as capital and strategic planning.

For more information about Ziegler, please visit us at http://www.ziegler.com.

About Ziegler:

Ziegler is a privately held, national boutique investment bank, capital markets and proprietary investments firm. It has a unique focus on healthcare, senior living and education sectors, as well as general municipal and structured finance. Headquartered in Chicago with regional and branch offices throughout the U.S., Ziegler provides its clients with capital raising, strategic advisory services, fixed income sales, underwriting and trading as well as Ziegler Credit, Surveillance and Analytics. To learn more, visit http://www.ziegler.com.

Certain comments in this news release represent forward-looking statements made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995. This client’s experience may not be representative of the experience of other clients, nor is it indicative of future performance or success. The forward-looking statements are subject to a number of risks and uncertainties, in particular, the overall financial health of the securities industry, the strength of the healthcare sector of the U.S. economy and the municipal securities marketplace, the ability of the Company to underwrite and distribute securities, the market value of mutual fund portfolios and separate account portfolios advised by the Company, the volume of sales by its retail brokers, the outcome of pending litigation, and the ability to attract and retain qualified employees.

# # #

Share article on social media or email:

NeuroFlow Awarded $750K from the National Science Foundation for SBIR Phase II


NeuroFlow has been awarded $750,000 from the National Science Foundation (NSF) Small Business Innovation Research (SBIR) program to support the expansion of its digital health platform enabling behavioral health integration in all care settings. This funding from the NSF, which conducts a rigorous merit-based review process, adds to NeuroFlow’s recent government awards.

The SBIR Phase II funding will support key technical initiatives including enhanced EHR integrations and data science efforts to accelerate the already impressive growth achieved by the company. The Philadelphia-based company has recently added key members to its leadership team across sales, engineering, and clinical operations to keep up with increased demand for its suite of products. NeuroFlow’s technology is being used by over 1,000 providers and organizations across the country to support the overall health of over 250,000 patients under contract, up from roughly 5,000 at the same time last year.

“NSF is proud to support the technology of the future by thinking beyond incremental developments and funding the most creative, impactful ideas across all markets and areas of science and engineering,” said Andrea Belz, Division Director of the Division of Industrial Innovation and Partnerships at NSF. “With the support of our research funds, any deep technology startup or small business can guide basic science into meaningful solutions that address tremendous needs.”

A major catalyst of that growth has been the data science underpinning NeuroFlow’s technology, enabling care teams to effectively risk stratify their patient populations and proactively identify at-risk individuals requiring additional support. The NSF funding will allow the team to increase investments in artificial intelligence regarding personalization and natural language processing. These initiatives, along with a combination of behavioral economics, gamification, and award-winning design result in a highly engaging solution, which is critical for remote collection of actionable data that providers can use to drive better outcomes and lower cost of care to the health care system at large.

“This funding will be immensely helpful in accelerating our growth and enabling us to make a greater impact when it comes to closing the gap between mental and physical health,” said the principal investigator on the project and NeuroFlow’s COO and Co-Founder Adam Pardes.

“Especially important in today’s climate, this recognition highlights the equal importance of behavioral health in the holistic treatment of a patient. It is validating for the NSF to support our research and value our technology as it relates to addressing a major healthcare issue affecting millions of lives every day.”

About NeuroFlow

NeuroFlow is a collaborative and measurement-based behavioral health platform integrated in all care settings. NeuroFlow’s suite of HIPAA-compliant, cloud-based tools simplify remote patient monitoring, improve risk stratification, and facilitate collaborative care. Hundreds of health systems, clinicians, and care teams are using NeuroFlow to bridge the gap between mental and physical health in order to improve patient outcomes and reduce the cost of care. Learn more at https://www.neuroflow.com

About America’s Seed Fund

America’s Seed Fund powered by the National Science Foundation (NSF) awards $200 million annually to startups and small businesses, transforming scientific discovery into products and services with commercial and societal impact. Startups working across almost all areas of science and technology can receive up to $1.75 million in non-dilutive funds to support research and development (R&D),helping de-risk technology for commercial success. America’s Seed Fund is congressionally mandated through the Small Business Innovation Research (SBIR) program. The NSF is an independent federal agency with a budget of about $8.1 billion that supports fundamental research and education across all fields of science and engineering. For more information, visit seedfund.nsf.gov

Share article on social media or email:

COVID-19, FIFRA, and EPA — A Conversation with Lisa Campbell


News Image

Bergeson & Campbell, P.C. (B&C®) is pleased to release a timely episode of the All Things Chemical™ podcast, “COVID-19, FIFRA, and EPA — A Conversation with Lisa Campbell.” In this episode, Lynn L. Bergeson, Managing Partner, B&C, and Lisa M. Campbell, one of the nation’s foremost legal experts on the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), a Partner at B&C, sat down to discuss U.S. Environmental Protection Agency (EPA) approval of products under FIFRA to combat COVID-19, the disease caused by the coronavirus.

Since the start of the coronavirus pandemic, EPA has been deluged with applications to approve new products and/or new uses of existing products to combat the virus. Lisa explains in this podcast how antimicrobial pesticide products play an important role in public health and safety, the kinds of antimicrobial product categories regulated by EPA (including sanitizers, sterilants, disinfectants, and others), how approved products are deployed to combat the novel pathogen that causes COVID-19, and what EPA is doing to fast-track the approval process to get products out there to protect public health. And as important as the federal EPA is in this regard, Lisa also explains the important role of state agencies in the pesticide product approval area. Lynn and Lisa round out their discussion on EPA’s efforts, along with other federal law enforcement offices, to stop the proliferation of virus scams, most notably the sale and distribution of antimicrobial products falsely claiming to be effective against the spread of the coronavirus.

The full podcast episode is available to stream online. Additional updates on regulatory efforts to approve products to combat COVID-19, along with commentary, can be found on B&C’s Pesticide Law and Policy Blog® and on the Regulatory Developments page of our website.

All Things Chemical™ engages listeners in intelligent, insightful conversation about everything related to industrial, pesticidal, and specialty chemicals and the law and business issues surrounding chemicals. B&C’s talented team of lawyers, scientists, and consultants will keep listeners abreast of the changing world of both domestic and international chemical regulation and provide analysis of the many intriguing and complicated issues surrounding this space. All Things Chemical™ is available now on iTunes, Spotify, Stitcher, and Google Play Music. Subscribe so you never miss an episode.

Share article on social media or email:

Global Biomedical Technologies Offers “Webinars on Wound Care” Series for Medical Professionals


“Properly treating wounds is an essential step in the healthcare process. These webinars are an excellent opportunity to discuss topics related to proper wound care.”- Dr. Mary Arnold Long, Clinical Education Director, Comfort Release®

Global Biomedical Technologies is excited to sponsor the next four in a series – “Webinars in Wound Care” – tailored for medical professionals. Join President, Dr. Howard Rosing and Director of Clinical Education, Dr. Mary Arnold Long, Wednesdays at 1:00 PM EST/10:00 AM PST. Participants may register here: https://comfortrelease.com/about-us/events/

“Properly treating wounds is an essential step in the healthcare process. These webinars are an excellent opportunity to discuss topics related to proper wound care,” said Arnold Long. “We will also answer important questions about how our patented Comfort Release® products create an optimal healing environment for wounds.”

The live-cast “Webinars in Wound Care” series schedule is as follows:

April 22 – How is Comfort Release® Different from Other Wound Care Products?

April 29 – What is MVTR, How is it Determined, and What are its Implications

May 8 – Clinical Product Evaluation: The Important Message About Comfort Release® Tape

May 13 – The Battle Round: The Market Leader vs. Comfort Release®

Rosing is a board-certified neurologist with over 30 years of experience. Rosing partnered with Dr. Yadong Wang and founded Comfort Release® to address Medical Adhesive-Related Skin Injuries – MARSI.

Long has over 30 years of nursing experience, She is a board-certified wound, ostomy and continence advanced practice nurse, a rehabilitation registered nurse, and an adult health clinical nurse specialist.

About Global Biomedical Technologies

Global Biomedical Technologies LLC. is a fast-growing medical technology company with innovations in chemistry and biomaterials. Committed to developing products that improve quality of patient care while remaining cost effective and practical for healthcare providers, we have invested extensively in research and development to find innovative solutions to today’s clinical challenges and to redefine care standards.

About Comfort Release®

Comfort Release® revolutionizes the landscape of medical adhesives by developing a patented oligomeric switch (OGS) technology; these products are made with a unique polymery to help people of all ages who have experienced the pain or injury associated with the removal of bandages, tapes or medical dressings. More information about Comfort Release® is available at http://www.comfortrelease.com.

Share article on social media or email:

Savage McVicker Insurance Earns “Diamond Achiever” Award in Ohio


News Image

“The members of the agency’s team are excellent business partners, providing quality, professional service to all clients they serve,” says Frankenmuth Insurance President and COO Fred Edmond.

Savage McVicker Insurance of Maumee, Ohio has been named “Diamond Achiever” for the state of Ohio by Frankenmuth Insurance for the second year in a row. The award is presented to the state agency that attained the highest overall percentage rating in profitability, growth and policy retention during the past year.

The results achieved by the team at Savage McVicker Insurance in 2019 have helped the agency once again become one of the most successful of Frankenmuth Insurance’s more than 600 independent agencies.

“We are proud to present this award to the management and staff at Savage McVicker Insurance,” says Frankenmuth Insurance President and COO Fred Edmond. “The members of the agency’s team are excellent business partners, providing quality, professional service to all clients they serve.”

To learn more about Savage McVicker Insurance, find them on Facebook or visit http://www.savagemcvicker.com.

# # #

Frankenmuth Insurance has been providing peace of mind for families and businesses for 150 years. Because insurance is both complicated and critical to people’s lives, Frankenmuth works exclusively with 645 independent agencies to provide business, home, auto and life insurance policies. With more than 750 employees, the company is headquartered in Frankenmuth, Michigan, and offers insurance products in 15 states. Frankenmuth Insurance is financially sound, with $1.7 billion in assets. The company has an A.M. Best rating of “A” (Excellent) and is a Ward’s 50® Top Performer. For more information visit fmins.com.

Share article on social media or email: